ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Preclinical Development and First-in-Human Imaging of the Integrin α
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05835570 (A Single-arm, Open-label, Single-center Clinical Study to the Evaluation of Integrin αvβ6-targeted Positron Emission Tomography), which is not on this map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-arm, Open-label, Single-center Clinical Study to the Evaluation of Integrin αvβ6-targeted Positron Emission Tomography (PET) for Malignant Tumors
Who cites it
65 citing papers in PubMed, 97 citations in OpenAlex.
- Article
- Linker Optimization in Lu-177 Labeled αvβ6-Integrin Binding Peptide Trimers for Targeted Radionuclide Therapy of Cancer.Molecular pharmaceutics · 2026Article
- Comparison of theMolecular therapy. Oncology · 2026Article
- First αvβ6-integrin targeted radioligand therapy of breast cancer using Lu-177-Therahexin.European journal of nuclear medicine and molecular imaging · 2026Article
- Immunohistochemical Evaluation of Integrin β6 Expression in Triple-Negative Breast Cancer as a Predictive Biomarker for Therapeutic and Diagnostic Radionuclides.Biomolecules · 2026Article
- Synthesis and preclinical development of a novelEJNMMI radiopharmacy and chemistry · 2026Article
- Radionuclide theranostics: advances and clinical applications in lung cancer.Frontiers in oncology · 2026Review
- PET/CT imaging of esophageal cancer targeting tumor cell specific αvβ6-integrin expression.European journal of nuclear medicine and molecular imaging · 2025Article
- Integrin αvβ6-Targeted PET/CT Imaging of Non-Small Cell Lung Cancer with [Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Observational
- Clinical Applications of Quantitative Imaging and Artificial Intelligence for Pancreatic Cance.Seminars in radiation oncology · 2025Review
- Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials.Tomography (Ann Arbor, Mich.) · 2025Review
- Preclinical Evaluation of an Integrin αBioconjugate chemistry · 2025Article
- Evaluation of VLA-4 (Integrin α4β1) as a Shared Target for Radiopharmaceutical Therapy across Solid Tumors.Molecular cancer therapeutics · 2025Article
- Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth.Journal of experimental & clinical cancer research : CR · 2025Article
- Selecting Targets for Molecular Imaging of Gastric Cancer: An Immunohistochemical Evaluation.Molecular diagnosis & therapy · 2025Article
- Using Integrin αInternational journal of radiation oncology, biology, physics · 2025Article
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine-Glycine-Aspartate) Strategies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Radiopharmaceuticals for Pancreatic Cancer: A Review of Current Approaches and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine.Chemical & biomedical imaging · 2024Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe study was undertaken to develop and evaluate the potential of an integrin α EXPERIMENTAL
designThe peptide α
results[
conclusionsThe clinical impact of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.